Blood Components Changes by Using of Ringer's Lactated as Detergent In Autologous Blood Cell Transfusion

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-31

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Placenta accreta spectrum (PAS) disorders are associated with increased maternal morbidity and mortality related to life-threatening hemorrhage, and greater potential need for blood transfusion. Clinical evidences have confirmed that the use of autologous blood cell transfusion is safe and effective for patients with obstetric haemorrhage. Normal saline is the solution recommended for red cell washing, administration and salvage. However, there is growing concern that normal saline is more toxic than balanced, buffered crystalloids such as Lactated Ringer's and Plasma-Lyte. The purpose of this study is to evaluate the blood components using of Ringer's Lactated by a prospective, single-center, open, and single-arm clinical trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Use of ROTEM Intraoperatively in Women With Placenta Accreta

NCT02729974

Placenta Accreta

ENROLLING_BY_INVITATION NA

The Effect of Human Albumin on Coagulation Competence and Hemorrhage

NCT02270723

Hemorrhage; Complicating Delivery, Coagulation Defect

UNKNOWN PHASE4

Prophylactic Intravenous Tranexamic Acid on Perioperative Blood Loss in Pregnant Women Undergoing Cesarean Section

NCT07078942

Pregnant Women Undergoing Cesarean Delivery

NOT_YET_RECRUITING PHASE4

ROLE OF PROPHYLACTIC TRANEXAMIC ACID IN PREVENTION OF POST-PARTUM HEMORRHAGE IN ELLSCS

NCT07002749

Post Partum Hemorrhage

NOT_YET_RECRUITING PHASE1

Life-saving Treatment With Dry-plasma for Massive Bleeding in an Pre-hospital Setting

NCT07012863

Bleeding Aortic Rupture Gastrointestinal Hemorrhage +3 more

NOT_YET_RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Placenta Accreta Spectrum

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1.

Using of Ringer's Lactated

Group Type OTHER

Ringer's Lactated

Intervention Type OTHER

Using of Ringer's Lactated In Autologous Blood Cell Transfusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ringer's Lactated

Using of Ringer's Lactated In Autologous Blood Cell Transfusion

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Between 18 and 45 years old
* Without health problem nor disease requiring regular medical treatment

Exclusion Criteria

* subject with contraindication for drawing blood
* Subject with physical or mental disability or restriction of liberty that would prevent autotransfusion

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No